The chemokine receptor 5 (CCR5), a member of the G proteincoupled receptor family (GPCR), is used by human immunodeficiency virus type 1 (HIV-1) with a R5 tropism as an entry receptor in addition to CD4. It is a key target for an antiviral action aiming at inhibiting the HIV-1 entry process. Only few data are available today regarding the mechanism involved in the intracellular trafficking process of CCR5. Understanding how CCR5 cell surface expression is regulated is particularly important with regard to HIV-1 entry inhibition. We set out to investigate whether CCR5 molecular determinants were involved in the postendocytic recycling and degradative pathways. We constructed progressive deletion mutants of the C-terminal domain of CCR5 that we stably expressed in HEK293 cells. All of the deletion mutants were expressed at the cell surface and were functional HIV-1 receptors. The deletion mutants were internalized after stimulation, but they lost their ability to recycle to the plasma membrane. They were rerouted toward a lysosomal degradative pathway. We identified here a sequence of four amino acids, present at the extreme C terminus of CCR5, that is necessary for the recycling of the internalized receptor, independently of its phosphorylation. A detailed analysis of this sequence indicated that the four amino acids acted as a postsynaptic density 95/discs-large/zona occludens (PDZ) interacting sequence. These results show that the CCR5 cytoplasmic domain bears a sequence similar to the "recycling signals" previously identified in other GPCRs. Drugs able to disrupt the recycling pathway of CCR5 may constitute promising tools for therapeutic treatment.The chemokine receptor 5 (CCR5) belongs to the superfamily of seven transmembrane domain proteins, coupled to the heterotrimeric G proteins (GPCR) (Lefkowitz, 2004). This receptor is mainly expressed on a subset of leukocytes that are recruited to sites of inflammation in response to its ligands including RANTES (CCL5), MIP-1␣ (CCL3), MIP-1 (CCL4), and MCP-2 (CCL8) (Moser et al., 2004). CCR5 stimulation triggers signal transduction cascades that promote a proper cell response. The endocytosis and postendocytic trafficking of CCR5 represent mechanisms that regulate such a response. Detailing these intracellular trafficking mechanisms is particularly important with regard to human immunodeficiency virus type 1 (HIV-1) entry inhibition. Together with CD4, CCR5 is used as a cell entry portal for the HIV-1 with a R5 tropism (Lederman et al., 2006). It is a key target for an antiviral action aiming at inhibiting the HIV-1 entry process (Princen and Schols, 2005). Some antiviral compounds, derived from chemokines, seem especially efficient. After interacting with CCR5, these compounds induce a sequestration of the receptor from the cell surface and thus prevent HIV-1 infection (Hartley et al., 2004). However, the protective mechanism of such compounds is not fully understood yet, mainly because of our lack of knowledge of the CCR5 intracellular trafficking mechani...